Novo Nordisk A/S (NYSE:NVO) Upgraded to Equal Weight at Morgan Stanley

Morgan Stanley upgraded shares of Novo Nordisk A/S (NYSE:NVOGet Rating) from an underweight rating to an equal weight rating in a research note issued to investors on Tuesday morning, Marketbeat Ratings reports.

Several other research firms also recently commented on NVO. Danske raised shares of Novo Nordisk A/S from a hold rating to a buy rating in a report on Thursday, February 3rd. Zacks Investment Research raised shares of Novo Nordisk A/S from a sell rating to a hold rating and set a $104.00 price objective for the company in a report on Friday, February 25th. JPMorgan Chase & Co. downgraded shares of Novo Nordisk A/S from an overweight rating to a neutral rating in a report on Monday, December 20th. Stifel Nicolaus assumed coverage on shares of Novo Nordisk A/S in a report on Monday, February 28th. They issued a buy rating for the company. Finally, Citigroup upgraded shares of Novo Nordisk A/S from a neutral rating to a buy rating in a research note on Wednesday, March 2nd. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of Hold and an average price target of $427.00.

Novo Nordisk A/S stock opened at $117.40 on Tuesday. Novo Nordisk A/S has a twelve month low of $70.24 and a twelve month high of $122.16. The firm has a 50 day moving average price of $106.49 and a 200-day moving average price of $105.94. The company has a market capitalization of $276.45 billion, a P/E ratio of 35.58, a P/E/G ratio of 2.76 and a beta of 0.51. The company has a quick ratio of 0.66, a current ratio of 0.86 and a debt-to-equity ratio of 0.18.

Novo Nordisk A/S (NYSE:NVOGet Rating) last released its earnings results on Wednesday, February 2nd. The company reported $0.73 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.71 by $0.02. The firm had revenue of $5.89 billion during the quarter, compared to the consensus estimate of $5.63 billion. Novo Nordisk A/S had a net margin of 34.00% and a return on equity of 72.70%. During the same period in the prior year, the firm earned $0.64 EPS. Equities analysts expect that Novo Nordisk A/S will post 3.33 EPS for the current fiscal year.

The business also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 5th. Stockholders of record on Monday, March 28th were given a dividend of $0.741 per share. The ex-dividend date was Friday, March 25th. This represents a dividend yield of 1.1%. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.56. Novo Nordisk A/S’s dividend payout ratio (DPR) is 44.85%.

Several institutional investors have recently bought and sold shares of the company. Capital International Investors raised its position in shares of Novo Nordisk A/S by 3.3% during the 4th quarter. Capital International Investors now owns 5,653,043 shares of the company’s stock valued at $631,330,000 after buying an additional 179,049 shares in the last quarter. BlackRock Inc. raised its position in shares of Novo Nordisk A/S by 1.3% during the 4th quarter. BlackRock Inc. now owns 3,464,132 shares of the company’s stock valued at $387,982,000 after buying an additional 45,842 shares in the last quarter. WCM Investment Management LLC purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at $278,383,000. Parametric Portfolio Associates LLC raised its position in shares of Novo Nordisk A/S by 3.5% during the 4th quarter. Parametric Portfolio Associates LLC now owns 2,428,890 shares of the company’s stock valued at $272,036,000 after buying an additional 82,760 shares in the last quarter. Finally, Royal Bank of Canada raised its position in shares of Novo Nordisk A/S by 3.9% during the 3rd quarter. Royal Bank of Canada now owns 1,693,852 shares of the company’s stock valued at $162,626,000 after buying an additional 62,829 shares in the last quarter. Hedge funds and other institutional investors own 10.80% of the company’s stock.

Novo Nordisk A/S Company Profile (Get Rating)

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.

Recommended Stories

Analyst Recommendations for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.